Evidence map›Paper›PMID 34251693›Full record

ArticleArtificial organs2021

Safety of electrooxidation for urea removal in a wearable artificial kidney is compromised by formation of glucose degradation products.

Maaike K van Gelder, Jeroen C Vollenbroek, Babette H Lentferink, Diënty H M Hazenbrink, Paul J Besseling, Frank Simonis, Silvia Giovanella, Giulia Ligabue, Maria A Bajo Rubio, Gianni Cappelli and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Artificial organs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Maaike K van GelderDepartment of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.
Jeroen C VollenbroekDepartment of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.
Babette H LentferinkDepartment of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.
Diënty H M HazenbrinkDepartment of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.
Paul J BesselingDepartment of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.
Frank SimonisNanodialysis BV, Oirschot, The Netherlands.
Silvia GiovanellaClinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
Giulia LigabueSurgical, Medical and Dental Department of Morphological Sciences, Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy.
Maria A Bajo RubioNephrology Service, Hospital La Paz Institute for Health Research (IdiPAZ), La Paz University Hospital and IRSIN, Madrid, Spain.
Gianni CappelliSurgical, Medical and Dental Department of Morphological Sciences, Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy.
Jaap A JolesDepartment of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.
Marianne C VerhaarDepartment of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.
Karin G F GerritsenDepartment of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.
University Medical Center Utrecht · NLUniversity of Modena and Reggio Emilia · ITCardialysis (Netherlands) · NLHospital La Paz Institute for Health Research · ES

Funding

European Commission 733169Nierstichting NT12.05
6 · The paper itself

Abstract

A major challenge for the development of a wearable artificial kidney (WAK) is the removal of urea from the spent dialysate, as urea is the waste solute with the highest daily molar production and is difficult to adsorb. Here we present results on glucose degradation products (GDPs) formed during electrooxidation (EO), a technique that applies a current to the dialysate to convert urea into nitrogen, carbon dioxide, and hydrogen gas. Uremic plasma and peritoneal effluent were dialyzed for 8 hours with a WAK with and without EO-based dialysate regeneration. Samples were taken regularly during treatment. GDPs (glyoxal, methylglyoxal, and 3-deoxyglucosone) were measured in EO- and non-EO-treated fluids. Glyoxal and methylglyoxal concentrations increased 26- and 11-fold, respectively, in uremic plasma (at [glucose] 7 mmol/L) and 209- and 353-fold, respectively, in peritoneal effluent (at [glucose] 100 mmol/L) during treatment with EO, whereas no change was observed in GDP concentrations during dialysate regeneration without EO. EO for dialysate regeneration in a WAK is currently not safe due to the generation of GDPs which are not biocompatible.

Indexed as

Electrochemical TechniquesKidneys, ArtificialDialysis SolutionsGlucoseHumansRenal DialysisUreaWearable Electronic DevicesDialysis SolutionsGlucoseUrea3-Deoxyglucosoneartificial kidneybiocompatibilityelectrooxidationglucose degradation productsglyoxalhemodialysismethylglyoxalperitoneal dialysisurea

Identifiers

PMID34251693
PMCPMC8597045
OpenAlexW3178690795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.